NEW YORK (360Dx) – Pelago Bioscience today announced it has been granted SEK3.6 million ($429,000) to use its technology to identify new oncology biomarkers for treating childhood leukemia.

The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples in order to identify biomarkers associated with best clinical outcomes for six commonly used cancer drugs, it said.